Drugmaker-sponsored research more likely to deem own drugs ‘cost effective,’ study shows

Thousands of cost-effectiveness analyses had a "significant sponsorship bias" regardless of disease treatment or study design since 1972, according to research published June 22 in The BMJ.

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive